Michelle Lin, MD
Neurology · Jacksonville, FLNPI 1568738383
Payments from drug & device makers
What this record shows
11 manufacturers reported payments, led by Alnylam Pharmaceuticals Inc. at 57.1% of the total. Reporting peaked in 2024 at $1,373 and has fallen 85.9% since, to $194 in 2025. That places this record below the midpoint for neurology clinicians in FL, where the typical reported total is $1,698.
Across 22 payments — averaging $89.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$1K
- Eisai Inc.$245
- Lundbeck LLC$200
- Biogen$125
- Orthofix Medical, Inc.$67
- Eli Lilly$57
- plus $152 from 5 others
Across 60 payments — averaging $4243.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alnylam Pharmaceuticals Inc.$255K
What the payments were for
- Travel & lodging$86544%
- Food & beverage$1,10956%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 9 | $1,128 |
| Eisai Inc. | 2 | $245 |
| Lundbeck LLC | 2 | $200 |
| Biogen | 1 | $125 |
| Orthofix Medical, Inc. | 1 | $67 |
| Eli Lilly | 2 | $57 |
| Polynovo North America LLC | 1 | $46 |
| AstraZeneca | 1 | $33 |
| Amgen | 1 | $27 |
| Medtronic | 1 | $24 |
| Livanova USA, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,974 in reported general payments places this provider in the 50th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 18 | $19,435 |
| Repatha SureclickEvolocumab | 26 | $15,529 |
| XareltoRivaroxaban | 11 | $12,954 |
| Rosuvastatin Calcium | 76 | $1,326 |
| Ezetimibe | 25 | $734 |
| Cilostazol | 29 | $549 |
| Atorvastatin Calcium | 53 | $542 |
| ClopidogrelClopidogrel Bisulfate | 29 | $416 |
| Losartan Potassium | 11 | $171 |
| FenofibrateFenofibrate Nanocrystallized | 12 | $61 |
Paid to pharmacies, not to this prescriber.
Other neurology in Jacksonville
- Steven ToenjesJacksonville$695K
- Zhigao HuangJacksonville$613K
- Kalina SandersJacksonville$544K
- Syed AsadJacksonville$302K
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
- Matthew BakerNaples$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.